

*The following translation of the press release is provided for information purposes only and is not intended to substitute the original French language document which has been published on November 7, 2011.*

## AVAILABILITY OF THE REPLY DOCUMENT

ESTABLISHED BY



**IPSOGEN**  
CANCER PROFILER

IN RESPONSE TO A TENDER OFFER INITIATED BY

**QIAGEN N.V.**



This press release has been prepared and published by Ipsogen in accordance with Articles 231-27 3° and 231-28 of the General Regulations of the French stock market authority (*Autorité des marchés financiers*) (the “AMF”).

Pursuant to Article L.621-8 of the French *Code monétaire et financier* Article 231-26 of the AMF General Regulations, the AMF granted visa No 11-502 on November 3, 2011 on the reply document established by Ipsogen in response to a tender offer initiated by Qiagen. The visa, according to the provisions of Article L.621-8-1 I of the French *Code monétaire et financier*, was granted after the AMF verified "*if the document is complete and understandable, and if the information which it contains are coherent*". It does not imply either the approval of the opportunity of the transaction, or the certification of the presented accounting and financial information.

In accordance with Article 231-28 of the AMF General Regulations, the “Other Information” document including the legal, financial and accounting information concerning Ipsogen was filed with the AMF on November 4, 2011.

The “Other Information” document and the reply document which received the visa No 11-502 on November 3, 2011 are available on the websites of Ipsogen ([www.ipsogen.com](http://www.ipsogen.com)) and the AMF ([www.amf-france.org](http://www.amf-france.org)) and may be obtained free of charge from:

**IPSOGEN S.A.**  
**Luminy Biotech Entreprises**  
**Parc scientifique de Luminy**  
**163, avenue de Luminy**  
**13288 Marseille Cedex 09**